Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the initial screening round of a randomized trial

Journal of the National Cancer Institute

Volumn 97, Issue 6, 2005, Pages 433-438

  Andriole, Gerald L ^a   Levin, David L ^b   Crawford, E David ^c   Gelmann, Edward P ^d   Pinsky, Paul F ^b   Chia, David ^e   Kramer, Barnett S ^f   Reding, Douglas ^g   Church, Timothy R ^h   Grubb, Robert L ^b   Izmirlian, Grant ^b   Ragard, Lawrence R ⁱ   Clapp, Jonathan D ^j   Prorok, Philip C ^b   Gohagan, John K ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g MARSHFIELD CLINIC   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ WESTAT   (United States)

^j INFORMATION MANAGEMENT SERVICES INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCREENING TEST; BLOOD; COLORECTAL TUMOR; FEMALE; HEALTH CARE QUALITY; LUNG TUMOR; MASS SCREENING; METHODOLOGY; MIDDLE AGED; OVARY TUMOR; PALPATION; PROSTATE TUMOR; RECTUM;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; OVARIAN NEOPLASMS; PALPATION; PATIENT COMPLIANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE; RECTUM;

EID: 20144368657     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji065     Document Type: Article

References (18)

1. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283-90.
2. Jacobsen SJ, Katusic SK, Bergstralh EJ, Oesterling JE, Ohrt D, Klee GG, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 1995;274:1445-9.
3. Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olson RM, Ross CA. Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology 1996;47:863-9.
4. Schroder FH, Kranse R, Rietbergen J, Hoedemaeke R, Kirkels W. The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam. Eur Urol 1999;35: 539-43.
5. Zoorob R, Anderson R, Cefalu C, Sidani M. Cancer screening guidelines. Am Fam Physician 2001;63:1101-12.
6. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the United States Preventive Services Task Force. Ann Intern Med 2002;137:917-29.
7. Prorok PC, Andriole GL, Bresalier RS, Buys SB, Chia D, Crawford ED, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000(6 Suppl);21:273S-309S.
8. Prostate. In: Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. AJCC manual for staging of cancer. 4th ed. Philadelphia (PA): Lippincott; 1992. p. 181-6.
9. Prostate. In: Fleming ID, Cooper JS, Henson, ED, Hutter RVP, Kennedy BJ, Murphy GP, et al., editors. AJCC cancer staging manual. 5th ed. Philadelphia (PA): Lippincott-Raven; 1997. p. 219-24.
10. Smith DS, Bullock AD, Catalona WJ. Racial differences in operating characteristics of prostate cancer screening tests. J Urol 1997;158:1861-6.
11. Smith DS, Humphrey PA, Catalona WJ. The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience. Cancer 1997;80:1852-6.
12. Thompson I, Carroll P, Coley C, Sweat G, McLeod D, Schellhammer P, et al. Prostate-specific antigen (PSA) best practice policy. American Urological Association. Oncology (Huntingt) 2000;14:267-86.
13. Fowler JE Jr, Bigler SA, Farabaugh PB. Prospective study of cancer detection in black and white men with normal digital rectal examination but prostate specific antigen equal or greater than 4.0 ng/mL. Cancer 2002;94: 1661-7.
14. Fowler JE, Bigler SA, Farabaugh PB, Wilson SS. Prostate cancer detection in black and white men with abnormal digital rectal examination and prostate specific antigen less than 4 ng/ml. J Urol 2000;164:1961-3.
15. Hoedemaeker RF, van der Kwast TH, Boer R, de Koning HJ, Roobol M, Vis AN, et al. Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Nat Cancer Inst 2001;93:1153-8.
16. Pinsky PF, Andriole GL, Kramer BS, Hayes RB, Prorok PC, Gohagan JK. Prostate biopsy following a positive screen in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Urol 2005;173:746-51.
17. Oesterling JE, Jacobsen SJ, Cooner WH. The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol 1995;153:1160-3.
18. Eastham JA, Riedel E, Scardino PT, Shike M, Fleisher M, Schatzkin A, et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2003;289:2695-700.